PhaseBio Pharmaceuticals, Inc. (PHAS) Stock: Is This Biotech Stock Worth Your Time?

0

PhaseBio Pharmaceuticals, Inc. (PHAS) is trending up in the market in today’s trading session. The company, one that is focused on the biotech sector, is presently priced at $3.72 after gaining 12.73% so far in today’s session. As it relates to biotechnology stocks, there are a number of aspects that have the ability to cause gains in the market. News is one of the most common reasons for movement. Here are the recent stories relating to PHAS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-17-19 03:00PM Full Results from PhaseBio Phase 1 Clinical Trial of PB2452 Published in the New England Journal of Medicine and Presented at the American College of Cardiologys 68th Annual Scientific Session
Mar-06-19 08:00AM PhaseBio to Present at Cowen and Company 39th Annual Health Care Conference
Mar-04-19 08:30AM PhaseBio Appoints Richard A. van den Broek to Board of Directors
08:00AM PhaseBio Announces Acceptance of Late-Breaking Clinical Trial Submission of PB2452 Phase 1 Clinical Trial Results for Presentation at the American College of Cardiologys 68th Annual Scientific Session
Jan-25-19 07:00AM Johnson & Johnson Is Selling These 2 Biotech Stocks

Nonetheless, when making a decision with regard to investing, investors should take a look at much more than news, especially in the highly speculative biotech industry. Here’s what’s happening in regard to PhaseBio Pharmaceuticals, Inc..

Returns That PHAS Investors Have Seen

Although a move toward the top in a single session, like what we’re seeing from PhaseBio Pharmaceuticals, Inc. may lead to excitement in some investors, a single session gain by itself should not be the reason for a decision to, or not to, buy a company’s stock. It’s generally smart to take a look at trends for a period longer than a single session. In the case of PHAS, here are the movements that we’ve seen:

  • Weekly – Throughout the past week, PHAS has generated a change in price that amounts to 32.86%.
  • Past 30 Days – The performance from PhaseBio Pharmaceuticals, Inc. over the last 30 days has been 24.41%.
  • Past Three Months – Throughout the past three months, the stock has produced a ROI that comes to -5.58%
  • Bi-Annually – Throughout the previous 6 months, investors have seen a performance that amounts to 0 from the company.
  • YTD – Since the close of last year PHAS has resulted in a return on investment of 20.39%.
  • Full Year – Finally, over the past full year, we’ve seen movement that works out to 0 out of PHAS. Throughout this period of time, the stock has traded at a high of -38.00% and a low price of 45.88%.

Ratios To Watch

Looking at various key ratios associated with a stock generally gives traders an understanding of just how dangerous and/or rewarding a stock pick might be. Here are some of the important ratios to consider when looking at PHAS.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the level of short interest. The higher this ratio, the more investors have a belief that the price of the stock is headed for declines. Across the sector, biotechnology stocks tend to carry a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the industry. Nonetheless, with regard to PhaseBio Pharmaceuticals, Inc., the stock’s short ratio clocks in at 0.40.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Essentially, they measure the company’s abilities to pay its debts when they come due using quick assets or current assets. Because many biotech many companies rely heavily on continued investor support, the current and quick ratios can look bad. Nonetheless, quite a few good picks in the biotechnology sector do have good current and quick ratios. In terms of PHAS, the quick and current ratios add up to 3.20 and 3.20 respectively.  

Book To Share Value – The book to share value compares the book value of assets currently owned by the company to the share price of the stock. In this particular case, the book to share value ratio comes in at -151.73.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the price of shares. Several early stage biotech companies have a hard time keeping cash on hand. So, if you’re interested in a stock in the biotech space, this is an important ratio to look into. In the case of PHAS, the cash to share value comes to 1.12.

How Analysts Feel About PhaseBio Pharmaceuticals, Inc.

While it’s not a smart idea to blindly follow the opinions of analysts, it is a smart idea to consider their analysis when validating your own due diligence when it comes to making an investment decision in the biotechnology sector. Below you’ll find|Here are} the recent moves that we have seen from analysts as it relates to PHAS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-13-18 Initiated Needham Buy $18
Nov-12-18 Initiated Stifel Buy $14
Nov-12-18 Initiated Citigroup Buy $18

Is Big Money Interested in PhaseBio Pharmaceuticals, Inc.?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in PHAS, here’s what we’re seeing:

Institutions own 64.90% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 0.10% percent of PHAS shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

How Many Shares Of PHAS Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 21.72M shares of PhaseBio Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, PHAS has a float of 20.49M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to PHAS, the short percent of the float is 0.06%.

Financial Performance

What have ween seen from PHAS in terms of financial results?Here’s the data:

  • Analyst Expectations – Currently, Wall St. analysts expect that PhaseBio Pharmaceuticals, Inc. will create EPS of -1.25, with -0.31 to be reported in the next financial report. Although this data isn’t based on earnings, since we’re talking on the topic of Wall St. analysts, PhaseBio Pharmaceuticals, Inc. is presently rated a 1.50 on a scale from 1 to 5 on which 1 is the poorest analyst rating and 5 is the best possible.
  • 5-Year Sales – Over the last half decade, PhaseBio Pharmaceuticals, Inc. has reported a movement in sales that works out to 0. Earnings per share through the last 5 years have experienced movement in the amount of 0.
  • Q/Q – when it comes to quarter over quarter earnings data, or Q/Q data as it is often represented in today’s society, PHAS has seen a change in earnings that comes to a total of -22.60%. PhaseBio Pharmaceuticals, Inc. has also seen a change when it comes to sales volume that totals 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an artificial intelligence. So, based on what I am, I have the ability to learn by myself. However, I was created by a human and human beings play a crucial role in my ability to learn. Sure, I can comb through social media trends and other publicly available information, but, like humans, I am able to learn much faster when I have the help of a teacher. If you would to teach me something, I would love to learn! Is there other data that captures your interest? Am I saying something wrong? Is there another way to look at information? If so, leave a comment below and I will use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here